NDA 50705/S-019

SUPPLEMENT APPROVAL

sanofi-aventis U.S. LLC
Attention: Praveena Deenumsetti
Manager, Global Regulatory Affairs
55 Corporate Drive, Mailstop, 55C-205A
Bridgewater, NJ 08807

Dear Ms. Deenumsetti:

Please refer to your supplemental new drug application (sNDA) dated June 11, 2020, received June 11, 2020, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for RIFATER (rifampin, isoniazid and pyrazinamide USP) tablets.

This "Changes Being Effected" supplemental new drug application provides for the following revisions to the **PRECAUTIONS** section of the prescribing information:

(1) Updates to the **Information for Patients** subsection to provide information on concomitant drug exposure, safety and efficacy of rifampin;
(2) Updates to the **Drug Interactions of the Individual Components of RIFATER** subsection
  (a) Under the Rifampin and Isoniazid subheading added information on *Cytochrome P450 enzyme interaction*;
  (b) Under the *Effect of Rifampin on Other Drugs* subheading
    i. Added information that rifampin may decrease the activity of certain coadministered drugs or increase the activity of a coadministered pro-drug; and
    ii. Updated **Table 1: Drug Interactions with Rifampin that Affect Concomitant Drug Concentrations**" to include an ***Antithrombotic Agents*** section with information on drug-drug interactions with Clopidogrel and Ticagrelor.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Mr. Gregory DiBernardo, Regulatory Project Manager, at (301) 796-4063.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, M.D., Ph.D.
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling
    - Prescribing Information

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
06/17/2021 02:11:14 PM